ANXA1 Binds and Stabilizes EGFR to Promote Nasopharyngeal Carcinoma Radioresistance

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Nasopharyngeal carcinoma (NPC) treatment is hindered by radioresistance.
• The role of Annexin A1 (ANXA1) in EGFR stabilization and its impact on NPC radioresistance remain unclear.

Purpose of the Study:

• To elucidate the mechanism by which ANXA1 stabilizes EGFR and influences NPC radioresistance.
• To investigate the potential of targeting the ANXA1-EGFR interaction for improving NPC radiosensitivity.

Main Methods:

• Investigated ANXA1's interaction with EGFR and its effect on EGFR ubiquitination and degradation using NPC cells.
• Assessed the impact of ANXA1 on NPC radioresistance in vitro and in vivo.
• Correlated ANXA1 and EGFR expression levels with NPC radiosensitivity and patient survival.
• Developed and tested an ANXA1-derived peptide to disrupt the ANXA1-EGFR interaction and enhance radiosensitivity.

Main Results:

• ANXA1 inhibits Cbl-mediated EGFR ubiquitination, thereby stabilizing EGFR and increasing NPC radioresistance.
• ANXA1 and EGFR expression levels are positively correlated in NPC tissues and are higher in radioresistant tissues.
• High co-expression of ANXA1 and EGFR predicts poorer patient survival.
• An ANXA1-derived peptide effectively downregulates EGFR and enhances NPC radiosensitivity in vitro and in vivo.

Conclusions:

• ANXA1 promotes NPC radioresistance by stabilizing EGFR.
• Combined ANXA1 and EGFR expression is a significant predictor of NPC radiosensitivity and patient prognosis.
• Targeting the ANXA1-EGFR interaction with a peptide represents a promising strategy for overcoming NPC radioresistance.